公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2008 | Primary mediastinal large B-cell lymphoma mimicking liposarcoma | CHUN-TA HUANG ; Huang W.C.; JIN-YUAN SHIH ; PAN-CHYR YANG | Medical Oncology | 0 | 0 | |
1998 | Primary pulmonary plasmacytoma with lobar consolidation: An unusual presentation | KUAN-YU CHEN ; Wu H.-D.; YIH-LEONG CHANG ; JIN-YUAN SHIH ; PAN-CHYR YANG | Journal of the Formosan Medical Association | 12 | 8 | |
2020 | Primary resistance to osimertinib despite acquired T790M | Chang L.-K.; YIH-LEONG CHANG ; JIN-YUAN SHIH | Respirology Case Reports | 3 | 2 | |
2005 | Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes | Sher Y.-P.; JIN-YUAN SHIH ; PAN-CHYR YANG ; Roffler S.R.; Chu Y.-W.; Wu C.-W.; CHIA-LI YU ; Peck K. | Clinical Cancer Research | 102 | 91 | |
2021 | Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan | SHANG-GIN WU ; WEI-YU LIAO ; KANG-YI SU ; SUNG-LIANG YU ; YEN-LIN HUANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | JTO Clinical and Research Reports | 16 | 0 | |
2018 | Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study | SHENG-KAI LIANG ; MENG-RUI LEE ; WEI-YU LIAO ; CHAO-CHI HO ; JEN-CHUNG KO ; JIN-YUAN SHIH | Oncotarget | 17 | 0 | |
2011 | The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma | YAO-WEN KUO ; JIH-SHUIN JERNG ; JIN-YUAN SHIH ; KUAN-YU CHEN ; CHONG-JEN YU ; PAN-CHYR YANG | Journal of Thoracic Oncology | 26 | 24 | |
2022 | Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One | YEN-TING LIN ; JIN-YUAN SHIH | Journal of Thoracic Oncology | 0 | 0 | |
2001 | Pulmonary pleomorphic (spindle) cell carcinoma: Peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma | YIH-LEONG CHANG ; Lee Y.-C.; JIN-YUAN SHIH ; CHEN-TU WU | Lung Cancer | 174 | 135 | |
2008 | Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response | Gow C.-H.; Chien C.-R.; YIH-LEONG CHANG ; Chiu Y.-H.; SUNG-HSIN KUO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Clinical Cancer Research | 132 | 125 | |
2020 | Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY | Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH ; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators | Cancer science | 17 | 12 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 397 | 341 | |
2018 | Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials | Yen C.-J.; Muro K.; Kim T.-W.; Kudo M.; JIN-YUAN SHIH ; Lee K.-W.; Chao Y.; Kim S.-W.; Yamazaki K.; Sohn J.; Cheng R.; Zhang Y.; Binder P.; Mi G.; Orlando M.; Chung H.C. | Journal of Global Oncology | 9 | 0 | |
2015 | Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene | Wu H.; JIN-YUAN SHIH ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 15 | 14 | |
2019 | A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor | LUN-CHE CHEN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Yang C.-Y. | Respirology Case Reports | 5 | 4 | |
2017 | Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 25 | 25 | |
2024 | Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer | JIN-YUAN SHIH ; Luo, Yung-Hung; Chang, Gee-Chen; Chang, John Wen-Cheng; Wang, Chin-Chou; Yang, Tsung-Ying; Fang, Wei-Tse; Shau, Wen-Yi | Journal of the Formosan Medical Association = Taiwan yi zhi | | | |
2017 | Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma | SHENG-KAI LIANG ; MIN-SHU HSIEH ; MENG-RUI LEE ; LI-TA KENG ; JEN-CHUNG KO ; JIN-YUAN SHIH | Oncotarget | 55 | 52 | |
2021 | Real-world insights into patients with advanced NSCLC and MET alterations | Bittoni M.; CHIH-HSIN YANG ; JIN-YUAN SHIH ; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. | Lung Cancer | 11 | 9 | |
2022 | Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma | CHIA-LING CHANG ; MIN-SHU HSIEH ; JIN-YUAN SHIH ; Lee, Yi-Hsuan; WEI-YU LIAO ; CHIA-LIN HSU ; CHING-YAO YANG ; KUAN-YU CHEN ; JIH-HSIANG LEE ; CHAO-CHI HO ; TZU-HSIU TSAI ; CHIH-HSIN YANG ; CHONG-JEN YU | Therapeutic advances in medical oncology | 1 | 1 | |